Drug Shortage in India: Causes and Hospital Response Guide
Why drug shortages happen in India — API import dependence, NPPA price control, recalls — and how hospital pharmacies build resilience against them.
This guide to drug shortage india covers what actually causes shortages in the Indian market, which government mechanisms exist to catch and correct them, and what a hospital pharmacy can do operationally so a national or regional shortage doesn't become a bedside emergency.
Why does India's API import dependence cause drug shortages?
India imports roughly 65-70% of its bulk drug and key starting material requirement, with dependence on China running close to 90% for some essential antibiotic APIs. A single supply disruption at the source can therefore cascade into a formulation shortage across dozens of Indian brands within weeks.
This isn't hypothetical. In March 2020, India restricted export of 26 formulations, including paracetamol and several antibiotics, when key starting materials stopped arriving from Chinese suppliers Indian pharma dependency analysis. Roughly 45-50% of China-sourced APIs feature in India's own essential medicines list, so exposure sits exactly where hospitals can least absorb a gap.
The concentration is molecule-specific. Penicillin-class antibiotics, azithromycin and several cephalosporins depend on Chinese intermediates for over 90% of national requirement, while other molecules are made domestically start to finish and rarely run short for this reason.
How does NPPA price control push manufacturers to stop making some drugs?
Price ceilings under the Drug Price Control Order (DPCO) 2013 fix a maximum sale price for scheduled formulations; when API costs rise faster than that ceiling, some manufacturers stop production rather than sell at a loss. NPPA data shows it approved 157 of 226 discontinuation applications for scheduled formulations between April 2020 and July 2023 NPPA scheduled formulation discontinuation data.
The clearest recent example is cisplatin and carboplatin, two chemotherapy drugs used across Indian oncology wards. Platinum-linked API costs rose sharply through 2025 and early 2026, and manufacturers holding NPPA-fixed ceiling prices of ₹7.26 per ml (cisplatin) and ₹60.49 per ml (carboplatin) had no legal room to pass the cost through. Supply tightened, oncologists reported rationing and delayed cycles, and NPPA responded in June 2026 by invoking Paragraph 19 of DPCO 2013, its extraordinary-circumstances clause, to raise both ceilings by 50%, to ₹10.89 and ₹90.74 per ml respectively NPPA cancer drug ceiling price notification.
Manufacturers do not need to formally discontinue a drug to create a shortage. Slowing production, deprioritising a low-margin SKU against a more profitable one, or simply not restocking distributors achieves the same effect without ever filing Form-IV. A ceiling price that looked adequate two years ago can quietly become the reason a drug is hard to find today.
What manufacturing and quality-control disruptions add to the shortage risk?
Beyond pricing and imports, routine good-manufacturing-practice (GMP) enforcement itself removes stock from the market when a batch fails testing. CDSCO's monthly Not-of-Standard-Quality (NSQ) surveillance flagged 168 medicines as substandard or spurious in March 2026 alone, part of 576 such flags in the first quarter of the year CDSCO NSQ detection data, March 2026.
Each NSQ flag triggers a recall through CDSCO's Drug Alert Management System, pulled from pharmacies and distributors nationwide with no advance warning to the facilities carrying it.
A single-plant manufacturer adds fragility. If one factory supplies the bulk of a formulation's national volume, a GMP shutdown, fire, or monsoon halt affects every hospital sourcing that brand, regardless of how well any pharmacy manages its own shelf. This is a supply-chain characteristic of the drug, not something a single facility's ordering discipline can fix.
What does CDSCO and the essential medicines list actually monitor?
CDSCO runs the regulatory surveillance layer (GMP inspection, NSQ batch testing, and the Pharmacovigilance Programme of India, or PvPI), while the National List of Essential Medicines (NLEM) defines which drugs the system is meant to keep continuously available for this drug shortage india tracking gap. Neither functions as a live, public shortage-tracking dashboard the way some other national regulators run one.
NPPA carries the closer parallel: it maintains its own shortage-facing page and has used its price-revision powers, as with cisplatin and carboplatin, specifically when a documented shortage was traced back to a price-cost mismatch NPPA shortage information. CDSCO's NSQ alerts and PvPI adverse-event reporting network feed the same regulatory picture from the quality and safety side CDSCO alerts.
For a hospital pharmacy, the practical read is that no single government feed will reliably warn you a shortage is coming. NPPA notifications, CDSCO NSQ alerts and distributor stock-out patterns each carry a piece of the signal, and a pharmacy that only watches one of them will see the shortage after it has already hit the shelf.
How does WHO track essential medicine shortages globally, and does it help India?
The World Health Organization documents that shortages cluster around old, off-patent, low-margin drugs with a narrow shelf life and few manufacturers, exactly the profile of many NPPA-scheduled formulations that drive drug shortage india cases. WHO's Global Action Plan sets an 80% availability-and-affordability target for essential diabetes, cardiovascular and respiratory medicines, a benchmark India's own price-control system is meant to support WHO on global medicine shortages.
WHO's framework is a diagnostic lens more than an operational lifeline for an individual Indian hospital. It confirms the shortage pattern is structural and global, not a one-off Indian policy failure, which matters when deciding whether to treat a shortage as temporary or as a recurring risk to plan around permanently.
How does PMBJP work as an access channel during a shortage?
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) runs thousands of Jan Aushadhi Kendras selling generic versions of common molecules at 50-90% below typical branded prices, giving patients an alternative channel when a specific branded product runs short PMBJP, Department of Pharmaceuticals. It covers 29 therapeutic categories, including cardiovascular and anti-infective drugs.
PMBJP helps a patient facing a branded stock-out at the retail counter. It does little for a hospital pharmacy mid-treatment, since a Jan Aushadhi Kendra is a separate retail point, not a hospital's own supply line, and switching a hospitalised patient's brand mid-therapy carries its own clinical risk. It is a genuine safety net for outpatients, not a substitute for a hospital's own sourcing resilience.
What should a hospital pharmacy's safety-stock policy actually cover?
A safety-stock policy needs a named minimum days-of-cover per essential molecule, reviewed against actual consumption, not one blanket rule for the whole formulary. Running 30 days of cover on a fast-moving antibiotic and 7 on a rarely used chemotherapy drug isn't inconsistent; it prices the two risks correctly.
The molecules needing the longest cover are the ones already flagged here: single-source APIs, DPCO-scheduled low-margin drugs with a discontinuation history, and single-plant-manufactured products. Ranking a formulary against these three factors, rather than stocking everything to the same depth, spends working capital on the shortages actually likely to happen.
| Risk factor | Example from this article | Suggested minimum cover |
|---|---|---|
| Single-country API dependence >85% | Penicillin-class antibiotics | 20-30 days |
| DPCO-scheduled, prior discontinuation filings in class | Chemotherapy platinum drugs | 15-20 days |
| Multi-source, domestic API | Most NLEM generics | 7-10 days |
Does multi-supplier sourcing actually reduce shortage exposure?
Yes, measurably: a pharmacy tied to one distributor inherits that distributor's own stock-out the moment it happens, while two or three qualified suppliers per essential molecule usually absorb one supplier's disruption without a patient-facing gap. This is standard risk-pooling, rarely implemented at a single hospital's scale because running three supplier relationships instead of one is real overhead.
This is where a centralised procurement model changes the arithmetic. A single hospital pharmacy negotiating alone has limited leverage to maintain three live supplier relationships for every essential molecule; a hub aggregating demand across several partner hospitals can justify that overhead once, and spread it across all of them. Medyzen's hub-and-spoke model pools demand forecasting across partner hospitals specifically so a shortage at one supplier can be covered by reallocating stock the hub already holds for another site, rather than each hospital discovering the gap independently. Medyzen's guide to managed hospital pharmacy services covers how this centralised structure works in practice.
What substitution protocol should a pharmacy have ready before a shortage hits?
A written substitution protocol names, in advance, which therapeutic alternative a pharmacist may dispense without a fresh prescription when a specific brand or formulation is unavailable, and which substitutions require physician sign-off first. Deciding this during an actual stock-out, under pressure, at the counter, produces inconsistent and sometimes unsafe decisions.
The protocol should distinguish molecule-level substitution (a different manufacturer's cisplatin) from therapeutic substitution (a different but clinically comparable drug), since the second always needs prescriber approval and the first often doesn't. Building this list against the same risk ranking used for safety stock — starting with single-source, price-control-exposed molecules — means the protocol is ready exactly where a shortage is statistically most likely to strike first. A hospital that pairs this with disciplined inventory tracking, as covered in Medyzen's guide to pharmacy inventory management and expiry stock, also reduces the odds that a real shortage is compounded by an internal stock record nobody trusts.
Sources
- 1China's Shadow over India's Medical Supply Chains — Observer Research Foundation
- 2NPPA Revises Ceiling Prices of Key Anti-Cancer Drugs, Tetanus Immunoglobulins and Essential Vaccines — reporting on official NPPA ceiling-price notification
- 3The National Pharmaceutical Pricing Authority Raises Price Cap on Cancer Drugs to Ease Supply Shortages — Chemical Industry Digest, citing NPPA notification
- 4National Pharmaceutical Pricing Authority — Shortage — NPPA, Government of India
- 5Latest Alerts — Central Drugs Standard Control Organisation
- 6CDSCO Detects 168 Not Of Standard Quality And Spurious Medicines In March — ETV Bharat, citing CDSCO NSQ data
- 7Addressing the global shortages of medicines, and the safety and accessibility of children's medication — World Health Organization
- 8Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — Department of Pharmaceuticals, Government of India
- 9The National Pharmaceutical Pricing Authority fixes ceiling prices in respect of the drugs specified in Schedule-I to DPCO 2013 — Press Information Bureau, Government of India
- 10NPPA fixed price of 4 scheduled formulations: August 2025 — reporting on NPPA scheduled-formulation discontinuation data
This article is for informational purposes and is not a substitute for professional pharmacy or regulatory advice.
FAQ
Frequently asked questions
No single cause dominates; the three most documented are heavy import dependence on Chinese APIs for specific antibiotic and chemotherapy molecules, NPPA price ceilings that make some scheduled formulations unprofitable, and periodic manufacturing or quality-control disruptions that pull batches from the market through recalls.
In June 2026, NPPA invoked Paragraph 19 of DPCO 2013, its extraordinary-circumstances provision, to raise ceiling prices of cisplatin and carboplatin by 50%, citing sharp API and platinum cost increases that had made continued production unviable at the previous ceiling and were causing chemotherapy rationing.
Not directly. PMBJP's Jan Aushadhi Kendras give outpatients an affordable generic alternative when a branded product is short at retail, but they are a separate retail channel from a hospital's own pharmacy supply line and cannot substitute for a hospital's internal sourcing and safety-stock strategy.
There is no single correct number; it should vary by molecule risk. Single-source, import-dependent or price-control-exposed drugs generally warrant 15-30 days of cover, while multi-source domestic generics can run safely on 7-10 days, freeing working capital for the higher-risk items.
It reduces exposure rather than eliminating it. A pharmacy sourcing an essential molecule from two or three qualified suppliers can usually absorb one supplier's disruption without a patient-facing gap, whereas single-supplier sourcing means that supplier's stock-out becomes the hospital's stock-out immediately.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.